(1R,2S,5S,6S,9S,10S)-6-acetyl-5-methylspiro[19-oxapentacyclo[10.5.2.01,13.02,10.05,9]nonadec-13-ene-17,6'-oxane]-2',5',15-trione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环己烷
• 英文名称: (1R,2S,5S,6S,9S,10S)-6-acetyl-5-methylspiro[19-oxapentacyclo[10.5.2.01,13.02,10.05,9]nonadec-13-ene-17,6'-oxane]-2',5',15-trione
• 化学式: C₂₅H₃₀O₆
• 分子量: 426.5
• InChiKey: RPSNKSRJTLBGNO-DRVYFJGSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  31
• 可旋转键数：
  1
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  86.7
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• [EN] PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT AND PREVENTION OF TRAUMA-INDUCED NEUROPATHOLOGY AND NEURODEGENERATION<br/>[FR] FORMULATIONS PHARMACEUTIQUES POUR LE TRAITEMENT ET LA PRÉVENTION DE LA NEUROPATHOLOGIE ET DE LA NEURODÉGÉNÉRESCENCE INDUITES PAR UN TRAUMATISME
  申请人：HENRY JAMES LORNE

  公开号：WO2014108808A2

  公开（公告）日：2014-07-17

  Novel multi-component formulations, procedures and methods for use in treating neuropathology and neurodegeneration incident to trauma are provided. Multi- component formulations of the invention comprise biologically active forms of any two, any three, or all four of at least one neurosteroid or neuroactive steroid, such as progesterone or synthetic progestin, at least one anti-epileptic or anticonvulsant, such as gabapentin, pregabalin or valproic acid, at least one NK-1 receptor antagonist, such as aprepitant, casopitant or vestipitant, at least one lithium-containing or lithium-related drug. The provided formulations are configured or adapted to prevent or reduce the incidence and severity of neurological damage caused by trauma, or the risk of such damage. Formulations, procedures and methods of the invention advantageously effect both neuroprotective actions to prevent or reduce secondary injuries, and neurotrophic actions to repair and restore cells and tissues affected by the trauma, and are especially useful in treating injury or trauma to nerve cells, to neural support cells and to neural support tissues.